Abstract:Hepatitis C virus (HCV) leads to severe liver diseases, including liver fibrosis, cirrhosis and hepatocellular carcinoma. Non-structural protein 3 helicase (NS3h) and non-structural protein 5B RNA-dependent RNA polymerase (NS5B) are involved in the replication of HCV RNA genome, and have been proved to be excellent targets for discovery of direct-acting antivirals. In this study, two high-throughput screening systems, fluorescence polarization (FP)-based ssDNA binding assay and fluorescence intensity (FI)-based dsRNA formation assay, were constructed to identify candidate NS3h and NS5B inhibitors, respectively. A library of approximately 800 small molecules and crude extracts, derived from marine microorganisms or purchased from the National Compound Resource Center, China, were screened, with three hits selected for further study. Natural compound No.3A5, isolated from marine fungi, inhibited NS3h activity with an IC50 value of 2.8 μM. We further demonstrated that compound No.3A5 inhibited the abilities of NS3h to bind ssDNA in electrophoretic mobility shift assay and to hydrolyze ATP. The NS3h-inhibitory activity of compound No.3A5 was reversible in our dilution assay, which indicated there was no stable NS3h-No.3A5 complex formed. Additionally, compound No.3A5 exhibited no binding selectivity on NS3h or single strand binding protein of Escherichia coli. In NS5B assays, commercial compounds No.39 and No.94 previously reported as kinase inhibitors were found to disrupt dsRNA formation, and their IC50 values were 62.9 and 18.8 μM, respectively. These results highlight how identifying new uses for existing drugs is an effective method for discovering novel HCV inhibitors. To our knowledge, all inhibitors reported in this study were originally discovered with HCV anti-non-structural protein activities in vitro.

Advance in the Research of the Nonstructural Protein NS2 of Hepatitis C Virus

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Recent Progress of Non-Structural 5A Protein(ns5a) Inhibitors As Anti-Hepatitis Virus C Agents

Recent Advance in Antiviral Drugs for Hepatitis C.

New Non-Nucleocide Ns5b Protein Inhibitors For The Treatment Of Chronic Hepatitis C Infection

HCV Non-Nucleoside NS5B Polymerase Inhibitors

An Insight into Hepatitis C Virus: In Search of Promising Drug Targets

Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein

New Developments in Small Molecular Compounds for Anti-Hepatitis C Virus (HCV) Therapy

Small Molecule NS5B RdRp Non-Nucleoside Inhibitors for the Treatment of HCV Infection: A Medicinal Chemistry Perspective.

An insight into the molecular characteristics of hepatitis C virus for clinicians

Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors

Recent Advances on the Synthesis of Hepatitis C Virus NS5B RNA-dependent RNA-polymerase Inhibitors.

Computational Study on the Wealth Conformations of Hepatitis C Virus Envelope Glycoprotein 2 and Role of Its Glycan Coat

[Research on Hepatitis C Virus Entry Inhibitor].

Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)

Targeting the life cycle of hepatitis C virus for novel antiviral treatment

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

The Development of Novel HCV NS3-4A Protease Inhibitors

NS5A Protein of HCV Enhances HBV Replication and Resistance to Interferon Response.

Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein